Search

Your search keyword '"Aleksander Lazaryan"' showing total 9 results
Start Over Author "Aleksander Lazaryan" Language undetermined
9 results on '"Aleksander Lazaryan"'

1. Figure S5 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

Author

Marco L. Davila, Frederick L. Locke, Claudio Anasetti, Christina A. Bachmeier, Brigett D. Brandjes, Marian Dam, Mohammad Hussaini, Ricardo Gonzalez, John Mullinax, Asmita Mishra, Taiga Nishihori, Julio C. Chavez, Bijal Shah, Farhad Khimani, Aleksander Lazaryan, Javier Pinilla, Biwei Cao, Xuefeng Wang, Kristen Spitler, Sae Bom Lee, Kayla Reid, Renyuan Bai, Hiroshi Kotani, Verena Staedtke, Michael Jain, and Rawan Faramand

Abstract

Noradrenaline levels in patients with grade 0, grade 1, grade 2 and grade 4 CRS respectively.

Published
2023
Full Text
View/download PDF

2. Data from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

Author

Marco L. Davila, Frederick L. Locke, Claudio Anasetti, Christina A. Bachmeier, Brigett D. Brandjes, Marian Dam, Mohammad Hussaini, Ricardo Gonzalez, John Mullinax, Asmita Mishra, Taiga Nishihori, Julio C. Chavez, Bijal Shah, Farhad Khimani, Aleksander Lazaryan, Javier Pinilla, Biwei Cao, Xuefeng Wang, Kristen Spitler, Sae Bom Lee, Kayla Reid, Renyuan Bai, Hiroshi Kotani, Verena Staedtke, Michael Jain, and Rawan Faramand

Abstract

Purpose:One of the challenges of adoptive T-cell therapy is the development of immune-mediated toxicities including cytokine release syndrome (CRS) and neurotoxicity (NT). We aimed to identify factors that place patients at high risk of severe toxicity or treatment-related death in a cohort of 75 patients with large B-cell lymphoma treated with a standard of care CD19 targeted CAR T-cell product (axicabtagene ciloleucel).Experimental Design:Serum cytokine and catecholamine levels were measured prior to lymphodepleting chemotherapy, on the day of CAR T infusion and daily thereafter while patients remained hospitalized. Tumor biopsies were taken within 1 month prior to CAR T infusion for evaluation of gene expression.Results:We identified an association between pretreatment levels of IL6 and life-threatening CRS and NT. Because the risk of toxicity was related to pretreatment factors, we hypothesized that the tumor microenvironment (TME) may influence CAR T-cell toxicity. In pretreatment patient tumor biopsies, gene expression of myeloid markers was associated with higher toxicity.Conclusions:These results suggest that a proinflammatory state and an unfavorable TME preemptively put patients at risk for toxicity after CAR T-cell therapy. Tailoring toxicity management strategies to patient risk may reduce morbidity and mortality.

Published
2023
Full Text
View/download PDF

3. Figure S1 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

Author

Marco L. Davila, Frederick L. Locke, Claudio Anasetti, Christina A. Bachmeier, Brigett D. Brandjes, Marian Dam, Mohammad Hussaini, Ricardo Gonzalez, John Mullinax, Asmita Mishra, Taiga Nishihori, Julio C. Chavez, Bijal Shah, Farhad Khimani, Aleksander Lazaryan, Javier Pinilla, Biwei Cao, Xuefeng Wang, Kristen Spitler, Sae Bom Lee, Kayla Reid, Renyuan Bai, Hiroshi Kotani, Verena Staedtke, Michael Jain, and Rawan Faramand

Abstract

Institutional management guidelines for CRS adapted from the CARTOX working group criteria.

Published
2023
Full Text
View/download PDF

4. Figure S3 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

Author

Marco L. Davila, Frederick L. Locke, Claudio Anasetti, Christina A. Bachmeier, Brigett D. Brandjes, Marian Dam, Mohammad Hussaini, Ricardo Gonzalez, John Mullinax, Asmita Mishra, Taiga Nishihori, Julio C. Chavez, Bijal Shah, Farhad Khimani, Aleksander Lazaryan, Javier Pinilla, Biwei Cao, Xuefeng Wang, Kristen Spitler, Sae Bom Lee, Kayla Reid, Renyuan Bai, Hiroshi Kotani, Verena Staedtke, Michael Jain, and Rawan Faramand

Abstract

Validation of serum cytokine samples using the Ella with the Luminex.

Published
2023
Full Text
View/download PDF

5. Tables S1-S4 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

Author

Marco L. Davila, Frederick L. Locke, Claudio Anasetti, Christina A. Bachmeier, Brigett D. Brandjes, Marian Dam, Mohammad Hussaini, Ricardo Gonzalez, John Mullinax, Asmita Mishra, Taiga Nishihori, Julio C. Chavez, Bijal Shah, Farhad Khimani, Aleksander Lazaryan, Javier Pinilla, Biwei Cao, Xuefeng Wang, Kristen Spitler, Sae Bom Lee, Kayla Reid, Renyuan Bai, Hiroshi Kotani, Verena Staedtke, Michael Jain, and Rawan Faramand

Abstract

Supplementary tables and figure legends

Published
2023
Full Text
View/download PDF

6. Figure S2 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

Author

Marco L. Davila, Frederick L. Locke, Claudio Anasetti, Christina A. Bachmeier, Brigett D. Brandjes, Marian Dam, Mohammad Hussaini, Ricardo Gonzalez, John Mullinax, Asmita Mishra, Taiga Nishihori, Julio C. Chavez, Bijal Shah, Farhad Khimani, Aleksander Lazaryan, Javier Pinilla, Biwei Cao, Xuefeng Wang, Kristen Spitler, Sae Bom Lee, Kayla Reid, Renyuan Bai, Hiroshi Kotani, Verena Staedtke, Michael Jain, and Rawan Faramand

Abstract

Institutional management guidelines for NT adapted from the CARTOX working group criteria.

Published
2023
Full Text
View/download PDF

7. Figure S4 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

Author

Marco L. Davila, Frederick L. Locke, Claudio Anasetti, Christina A. Bachmeier, Brigett D. Brandjes, Marian Dam, Mohammad Hussaini, Ricardo Gonzalez, John Mullinax, Asmita Mishra, Taiga Nishihori, Julio C. Chavez, Bijal Shah, Farhad Khimani, Aleksander Lazaryan, Javier Pinilla, Biwei Cao, Xuefeng Wang, Kristen Spitler, Sae Bom Lee, Kayla Reid, Renyuan Bai, Hiroshi Kotani, Verena Staedtke, Michael Jain, and Rawan Faramand

Abstract

Correlation of baseline IL6 levels(pg/mL) with IL6 levels collected on day of axi-cel infusion (A) and peak levels (B)

Published
2023
Full Text
View/download PDF

8. Figure S6 from Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel

Author

Marco L. Davila, Frederick L. Locke, Claudio Anasetti, Christina A. Bachmeier, Brigett D. Brandjes, Marian Dam, Mohammad Hussaini, Ricardo Gonzalez, John Mullinax, Asmita Mishra, Taiga Nishihori, Julio C. Chavez, Bijal Shah, Farhad Khimani, Aleksander Lazaryan, Javier Pinilla, Biwei Cao, Xuefeng Wang, Kristen Spitler, Sae Bom Lee, Kayla Reid, Renyuan Bai, Hiroshi Kotani, Verena Staedtke, Michael Jain, and Rawan Faramand

Abstract

Myeloid and Tregs associated with severe CRS in patients treated with axi-cel.

Published
2023
Full Text
View/download PDF

9. A single institution review of adjuvant therapy outcomes for resectable pancreatic adenocarcinoma: outcome and prognostic indicators

Author

Michael Byrne, R. E. Tsao, Robert Pelley, Richard D. Kim, Paul Elson, Ann Tan, Khaldoun Almhanna, and Aleksander Lazaryan

Subjects
Oncology, Adult, Male, medicine.medical_specialty, medicine.medical_treatment, Adenocarcinoma, Pancreaticoduodenectomy, Pancreatic cancer, Internal medicine, medicine, Adjuvant therapy, Humans, Survival rate, Lymph node, Aged, Aged, 80 and over, Univariate analysis, business.industry, Gastroenterology, Age Factors, Bilirubin, Middle Aged, medicine.disease, Alkaline Phosphatase, Prognosis, Elevated alkaline phosphatase, Radiation therapy, Pancreatic Neoplasms, Survival Rate, medicine.anatomical_structure, Treatment Outcome, Chemotherapy, Adjuvant, Lymphatic Metastasis, Surgery, Female, Radiotherapy, Adjuvant, medicine.symptom, business
Abstract

A large single-institution series of patients who recently underwent pancreaticoduodenectomy for resectable pancreatic cancer was analyzed to determine prognostic factors for overall survival, including the impact of adjuvant radiation and chemotherapy. Medical records were reviewed for 179 consecutive patients treated at The Cleveland Clinic with pancreaticoduodenectomy for resectable pancreatic adenocarcinoma from 1999 to 2006. Clinical data were collected, and Kaplan–Meier method was used to estimate overall survival. Univariate and multivariate analysis was performed. One hundred seventy-nine patients with pT1-3N0-1M0 pancreatic cancer met the above criteria. But analysis was available for 158 patients. Median age at diagnosis was 67 (range 35–93). Peri-operative mortality rate was 0.6%. On univariate analysis, poor prognostic factors for overall survival were poorly differentiated histology, lymph node positive disease, elevated alkaline phosphatase, elevated total bilirubin, elevated AST, age at diagnosis >70, and high T stage. On multivariate analysis, poorly differentiated histology (p = .001), age >70 (p = .007), lymph node involvement (≥3 positive vs

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results